Trial Profile
Multicenter Phase II Clinical Study on the Safety and Efficacy of Nilotinib in Patients with Chronic Myelogenous Leukemia, Chronic Phase Patients with Major Molecular Response.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2018
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms STAT1
- 01 Aug 2018 Primary endpoint (CMR rate at 24 months after the initiation of nilotinib treatment) has been met as per results published in the International Journal of Hematology.
- 01 Aug 2018 Results published in the International Journal of Hematology
- 25 Jun 2017 Results of association of nilotinib trough concentraion and liver dysfunction data from two studies (STAT1 and STAT2) presented at the 22nd Congress of the European Haematology Association